Boston Scientific will support its largest business segment, cardiovascular, by rolling out a cloud-based digital care solution that's aimed at giving hospitals greater insight into their chronic cardiovascular population and patients. To do so, it's teamed up with software giant Accenture.
Dr. Ken Stein, the chief medical officer of Boston Scientific's rhythm management division, said that industry and the healthcare system are not doing a good job of ensuring women are adequately treated with cardiology devices like pacemakers and implantable defibrillators.
Boston Scientific is facing more legal pushback over defective vaginal mesh devices, but this time, it's not from women who claim injuries or serious side effects from the products. A Houston-based law firm is cracking down on the company for allegedly smuggling mesh materials out of China and putting women at risk for serious side effects.
At the J.P. Morgan Healthcare conference in San Francisco, Boston Scientific officials said they are shifting the balance of the company into faster-growth markets like electrophysiology and neuromodulation, as opposed to mature ones like drug-eluting stents and pacemakers.
Boston Scientific is rolling out a disposable digital ureteroscope called LithoVue, which is an endoscope specifically designed for minimally invasive means to examine the kidney, ureter and bladder. The device is designed to offer high-quality digital visualization and navigation, but it's for a single use only.
The FDA publicized three previously disclosed recalls from Boston Scientific, Draeger and Insulet. From time to time, the agency sends out alerts about important recalls over website and via email, adding a sense of urgency to the trio of Class 1 corrective actions, which are reserved for situations in which the use of the faulty devices may cause serious injury or death.
Unlike most medical technology, the only FDA-approved transcatheter implant to ward off stroke competes not with other devices but with blood-thinning drugs. As a result, the adoption of Boston Scientific's Watchman is being handled with great care by the medical community and will be influenced greatly by the numerous studies on its paradigm-shifting approach to limiting the harm caused by atrial fibrillation.
The rising cost of prescription drugs has just about everyone up in arms, with lawmakers, presidential hopefuls such as Hillary Clinton and the public criticizing companies' prices hikes for certain meds. As the chorus of discontent reaches a crescendo, devicemakers are benefiting from the noise.
NxThera has gotten a $40 million cash infusion to market its steam-based device to treat problems associated with benign prostate hyperplasia. The startup successfully drafted medical device heavyweight Boston Scientific to lead the round.
Boston Scientific announced simultaneous approval to market its AngioJet ZelanteDVT thrombectomy catheter for treating deep vein thrombosis in the U.S., Europe and other countries that accept the CE mark.